ClinicalTrials.gg
CompletedNCT06540716Updated May 22, 2026

Inspire Singapore Study

An interventional study of Inspire System in Obstructive Sleep Apnea, OSA and Sleep Apnea, sponsored by Inspire Medical Systems, Inc.. Completed at 2 sites in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Inspire Medical Systems, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. — 5 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Inspire Medical Systems, Inc..

Started
2024
the only one that year
No phase
6 of 13
2 open now
Registered
10th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., this one is the only one that started in 2024, is one of 6 with no phase, and was the 10th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

5 of the 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc. are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Inspire Medical Systems, Inc., or all of them as a file.
02

Study summary

Prospective, multicenter, open-label study designed to confirm device performance of Inspire system in Singapore.

Read the detailed description

Patients who meet study eligibility criteria will be implanted with an Inspire system and followed for 6 months post-therapy-activation. Study subjects will undergo in-lab sleep studies to confirm inspiratory overlap (1st PSG, after therapy activation), titrate the therapy (2nd PSG, at 3 months post-activation) and confirm therapy performance (3rd PSG, at 6 months post-activation). Symptoms and quality of life (assessed by ESS and FOSQ), therapy adherence, and adverse events will also be collected and reported.

03

Conditions studied

  • Obstructive Sleep Apnea
  • OSA
  • Sleep Apnea
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Diagnosis of moderate to severe OSA (AHI 15-65)
  • Failure of, or intolerance to CPAP

Main Exclusion Criteria:

  • Central + mixed apneas > 25% of total AHI
  • Presence of complete concentric collapse (CCC)
  • Compromised neurological control of the upper airway.

Other eligibility criteria may apply.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Other
    Hypoglossal nerve stimulation

    Device: Inspire System

Interventions

  • DeviceInspire System

    Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.

06

What researchers measure

Primary outcomes

  1. Inspiratory Overlap

    Percentage (%) of inspiratory overlap as measured by polysomnography (PSG)

    Time frame: 0-3 months post-therapy activation

Secondary outcomes

  1. Therapy Effectiveness

    Change in Apnea-Hypopnea Index (AHI)

    Time frame: 6 months post-therapy activation

  2. Symptom Reduction

    Mean Epworth Sleepiness Scale (ESS) Score of less than 10. ESS scores range from 0-24 with a score of less than 10 indicating normalized daytime sleepiness.

    Time frame: 6 months post-therapy activation

Other outcomes

  1. Rate of Adverse Events

    Report of procedure/device/therapy-related adverse events

    Time frame: 6 months post-therapy activation

  2. Therapy Adherence

    Mean therapy use (hours per day)

    Time frame: 6 months post-therapy activation

  3. Functional Outcomes of Sleep Questionnaire (FOSQ) Score

    Changes in Functional Outcomes of Sleep Questionnaire (FOSQ). Total score range 5-20, with higher scores indicating better functional status.

    Time frame: 6 months post-therapy activation

  4. Inspiratory Overlap

    Percentage (%) of inspiratory overlap as measured by polysomnography (PSG)

    Time frame: 6 months post-therapy activation

07

Study locations

2 sites
  • National University Hospital
    Singapore, Singapore
  • Singapore General Hospital
    Singapore, Singapore
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2025, 11 months.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 11 months is close to that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 6, 2024
StartActual
Jul 25, 2024
Primary completionActual
Jul 17, 2025
CompletionActual
Dec 1, 2025
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06540716
Lead sponsor
Inspire Medical Systems, Inc.
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Jul 25, 2024
Primary completion
Jul 17, 2025
Completion
Dec 1, 2025
Last update
May 22, 2026

Study contacts

Toh Song Tar, MD
principal investigator · Singapore General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion